{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=A-Thalassemia&page=3",
    "query": {
      "condition": "A-Thalassemia",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 100,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=A-Thalassemia&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=A-Thalassemia&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T15:50:03.356Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01522547",
      "title": "Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anemia, Sickle Cell"
      ],
      "interventions": [
        {
          "name": "pomalidomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 12,
      "start_date": "2007-08-01",
      "completion_date": "2013-12-01",
      "has_results": false,
      "last_update_posted_date": "2019-11-08",
      "last_synced_at": "2026-10-08T15:50:03.356Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01522547"
    },
    {
      "nct_id": "NCT04143724",
      "title": "Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "ACE-536",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 99,
      "start_date": "2019-11-07",
      "completion_date": "2035-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-08T15:50:03.356Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04143724"
    },
    {
      "nct_id": "NCT01186419",
      "title": "Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Transfusional Iron Overload",
        "Beta-thalassemia"
      ],
      "interventions": [
        {
          "name": "SPD602 (FBS0701, SSP-004184)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 51,
      "start_date": "2010-08-13",
      "completion_date": "2013-01-08",
      "has_results": true,
      "last_update_posted_date": "2021-06-10",
      "last_synced_at": "2026-10-08T15:50:03.356Z",
      "location_count": 2,
      "location_summary": "Oakland, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01186419"
    },
    {
      "nct_id": "NCT04938635",
      "title": "Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "VIT-2763 60 mg QD",
          "type": "DRUG"
        },
        {
          "name": "VIT-2763 60 mg BID",
          "type": "DRUG"
        },
        {
          "name": "VIT-2763 120 mg BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vifor (International) Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-09-20",
      "completion_date": "2023-07",
      "has_results": false,
      "last_update_posted_date": "2022-11-10",
      "last_synced_at": "2026-10-08T15:50:03.356Z",
      "location_count": 1,
      "location_summary": "Whittier, California",
      "locations": [
        {
          "city": "Whittier",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04938635"
    },
    {
      "nct_id": "NCT06813924",
      "title": "A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers Sickle Cell Disease, Thalassemia"
      ],
      "interventions": [
        {
          "name": "Etavopivat",
          "type": "DRUG"
        },
        {
          "name": "Digoxin",
          "type": "DRUG"
        },
        {
          "name": "Pitavastatin",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 37,
      "start_date": "2025-02-06",
      "completion_date": "2025-05-27",
      "has_results": false,
      "last_update_posted_date": "2026-09-29",
      "last_synced_at": "2026-10-08T15:50:03.356Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06813924"
    },
    {
      "nct_id": "NCT00176852",
      "title": "Stem Cell Transplant for Hemoglobinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Thalassemia",
        "Severe Congenital Neutropenia",
        "Diamond-Blackfan Anemia",
        "Shwachman-Diamond Syndrome"
      ],
      "interventions": [
        {
          "name": "Busulfan, Fludarabine, ATG, TLI",
          "type": "DRUG"
        },
        {
          "name": "Busulfan, Cyclophosphamide, ATG, GCSF",
          "type": "DRUG"
        },
        {
          "name": "Campath, Fludarabine, Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Stem cell infusion",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "Up to 50 Years"
      },
      "enrollment_count": 22,
      "start_date": "2002-06",
      "completion_date": "2020-01",
      "has_results": true,
      "last_update_posted_date": "2020-02-27",
      "last_synced_at": "2026-10-08T15:50:03.356Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00176852"
    },
    {
      "nct_id": "NCT01419704",
      "title": "Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Anemia, Sickle Cell",
        "Complex and Transfusion-dependent Hemoglobinopathies",
        "Thalassemia",
        "Diamond-Blackfan Anemia",
        "Bone Marrow Failure Syndromes",
        "Alpha-Thalassemia",
        "Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "Enriched Hematopoetic Stem Cell Infusion",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Talaris Therapeutics Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "Up to 45 Years"
      },
      "enrollment_count": 0,
      "start_date": "2011-05",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2023-03-03",
      "last_synced_at": "2026-10-08T15:50:03.356Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Louisville, Kentucky • Durham, North Carolina",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01419704"
    },
    {
      "nct_id": "NCT00143039",
      "title": "Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hydrops Fetalis",
        "Fetal Growth Retardation"
      ],
      "interventions": [
        {
          "name": "Tandem MS test for inborn errors of metabolism",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Obstetrix Medical Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2006-03",
      "completion_date": "2009-08",
      "has_results": false,
      "last_update_posted_date": "2014-12-19",
      "last_synced_at": "2026-10-08T15:50:03.356Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Laguna Hills, California • Long Beach, California + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00143039"
    },
    {
      "nct_id": "NCT05444894",
      "title": "EDIT-301 for Autologous Hematopoietic Stem Cell Transplant (HSCT) in Participants With Transfusion-Dependent Beta Thalassemia (TDT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Transfusion Dependent Beta Thalassemia",
        "Hemoglobinopathies",
        "Thalassemia Major",
        "Thalassemia Intermedia"
      ],
      "interventions": [
        {
          "name": "EDIT-301",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Editas Medicine, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "18 Years to 35 Years"
      },
      "enrollment_count": 9,
      "start_date": "2022-04-29",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2025-04-02",
      "last_synced_at": "2026-10-08T15:50:03.356Z",
      "location_count": 7,
      "location_summary": "Oakland, California • Minneapolis, Minnesota • New York, New York + 3 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05444894"
    },
    {
      "nct_id": "NCT07517133",
      "title": "A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Transfusion-dependent Alpha-Thalassemia",
        "Non-Transfusion-dependent Beta-Thalassemia"
      ],
      "interventions": [
        {
          "name": "Mitapivat",
          "type": "DRUG"
        },
        {
          "name": "Placebo Matching Mitapivat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 45,
      "start_date": "2026-09",
      "completion_date": "2032-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-08T15:50:03.356Z",
      "location_count": 5,
      "location_summary": "Palo Alto, California • Atlanta, Georgia • New York, New York + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07517133"
    }
  ]
}